Korro reports second quarter 2025 financial results and provides business updates

— interim readout from phase 1/2a rewrite clinical trial of krro-110 on track for the second half of 2025 — completed dosing of over 80% of planned rewrite healthy volunteers across multiple single ascending dose (sad)  cohorts with no treatment emergent serious adverse events (saes) or dose limiting toxicities observed — european medicines agency (ema) granted orphan drug designation to krro-110 for the treatment of alpha-1 antitrypsin deficiency (aatd) — development candidate for korro's rare metabolic disorder program will be announced by end of 2025 — ended second quarter 2025 with $119.6 million in cash, cash equivalents and marketable securities   cambridge, mass., aug. 12, 2025 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing rna for both rare and highly prevalent diseases, today reported financial results for the second quarter of 2025 and provided a business update.
KRRO Ratings Summary
KRRO Quant Ranking